Icon Plc (NASDAQ:ICLR) is a contract research organization (“CRO”). In the Q3 2024 letter, I highlighted our investment in Medpace another CRO that directly competes with Icon.

Icon PLC (ICLR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ICON plc delivered third-quarter 2024 adjusted earnings per share of $3.35, up 1.5% from the year-ago period’s figure. However, the metric missed the Zacks Consensus Estimate by 12.99%.

More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain ...

Icon PLC (ICLR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.47 per share a year ago. These figures ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial intelligence (AI) tools ...

Icon PLC expects full-year earnings in the range of $12.75 to $14.25 per share, with revenue in the range of $7.75 billion to $8.15 billion. _____ This story was generated by Automated Insights ...

Icon PLC (ICLR) delivered earnings and revenue surprises of 3.57% and 0.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?